[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335687-105":59,"doc-detail-335687-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","detection-of-a-novel-dna-methylation-marker-panel-for-esophageal-cancer-diagnosis-using-circulating-tumor-dna","Detection of a novel DNA methylation marker panel for esophageal cancer diagnosis using circulating tumor DNA","","Esophageal cancer (ECa) has rising incidence and poor prognosis, and while endoscopy can detect disease in high-risk individuals, it is unsuitable for large-scale screening because it is invasive and inconvenient. This study developed a blood-based DNA methylation gene panel and evaluated diagnostic performance in 304 participants (203 ECa cases, 101 controls). Methylation of SEPTIN9, TFPI2, and FHIT was analyzed across ECa, benign esophageal disease, and healthy control groups using ROC metrics (AUC, sensitivity, specificity, 95% CIs) and comparison to pathological examination, with biomarker–pathology agreement assessed by kappa statistics. The panel achieved strong discrimination, with an overall AUC of 0.925, sensitivity 79.8%, and specificity 95.0%, and high consistency versus the pathological gold standard.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/detection-of-a-novel-dna-methylation-marker-panel-for-esophageal-cancer-diagnosis-using-circulating-tumor-dna/335687/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/detection-of-a-novel-dna-methylation-marker-panel-for-esophageal-cancer-diagnosis-using-circulating-tumor-dna/335687.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is a new blood-based diagnostic approach needed for esophageal cancer?","Question",{"text":112,"@type":113},"Endoscopy is recommended for high-risk detection but is not suitable for broad screening due to invasiveness and inconvenience. Esophageal cancer also has limited early detection and poor outcomes without timely diagnosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which DNA methylation biomarkers were included in the proposed panel?",{"text":117,"@type":113},"The panel measured DNA methylation levels of SEPTIN9, tissue factor pathway inhibitor 2 (TFPI2), and the fragile histidine triad gene (FHIT).",{"name":119,"@type":110,"acceptedAnswer":120},"How accurate was the panel compared with pathological examination?",{"text":121,"@type":113},"The panel showed strong discrimination with an overall ROC AUC of 0.925 (95% CI 0.889–0.952), sensitivity of 79.8%, and specificity of 95.0%. Agreement with the gold-standard pathological examination was supported by a kappa value of 0.725.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335687,1790387784,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Zheng et al. BMC Cancer (2024) 24:1578 [https://doi.org/10.1186/s12885-024-13301-7](https://doi.org/10.1186/s12885-024-13301-7)  \nBMC Cancer  \n RESEARCH Open Access  \nDetection of a novel DNA methylation  \nmarker panel for esophageal cancer diagnosis using circulating tumor DNA  \nYan Zheng1†, Wenqun Xing1†, BingWei2,3, Xianben Liu1, Guanghui Liang1, Dongfeng Yuan1, Ke Yang2,3, Weizhen Wang2,3, Dongxu Chen2,3 and Jie Ma2,3*  \nAbstract  \nBackground Esophageal cancer (ECa) is one of the most deadly cancers, with increasing incidence worldwide and poor prognosis. While endoscopy is recommended for the detection of ECa in high-risk individuals, it is not suitable for large-scale screening due to its invasiveness and inconvenience.  \nMethods In this study, a novel gene methylation panel was developed for a blood-based test, and its diagnostic efficacy was evaluated using a cohort of 304 participants (203 cases, 101 controls) . The assessment focused on the DNA methylation levels of SEPTIN9, tissue factor pathway inhibitor 2 (TFPI2), and the fragile histidine triad gene (FHIT) in patients with ECa, benign esophageal disease, and healthy controls. The receiver operating characteristic (ROC) curve was generated for the panel to calculate the area under the curve (AUC), sensitivity, specificity, and 95% confidence intervals (CIs), along with a comparison to the gold standard of pathological examination. The consistency between biomarker and pathological diagnosis was evaluated with kappa analysis conducted with IBM SPSS Statistics. The Chi-square test or Fisher’s exact test was utilized to assess the association of test positivity with demographic characteristics.  \nResults In patients with ECa, SEPTIN9, TFPI2, and FHIT DNA methylation levels were significantly higher compared to those with benign esophageal disease or healthy controls. The panel demonstrated promising potential as a noninvasive tool for distinguishing malignant tumors from both healthy controls and benign esophageal diseases, achieving an area under the ROC curve of 0.925 (95% CI: 0 .889–0. 952), with a sensitivity of 79. 8%[95% CI 73.6—85. 1%] and specificity of 95. 0%[95% CI 88.8—98.4%] . In particular, the panel showed exceptional diagnostic efficiency for stage 0, I, and II cancer patients with sensitivity at 69 . 0, 75. 5%, and 78. 9%, respectively. The comparison revealed a Kappa value of 0.725 between RT-PCR testing and the established gold standard of pathological examination, indicating a high level of consistency. Additionally, there was no bias in diagnostic efficiency based on age, gender, or the presence of other malignancies (non-esophageal cancers) .  \nConclusions The study’s findings suggested that the DNA methylation biomarkers panel holds promise as a noninvasive and convenient diagnostic test for ECa. The panel’s ability to distinguish malignant tumors from benign  \n†Yan Zheng and Wenqun Xing contributed equally to this work.  \n*Correspondence: Jie Ma[majie_fzbl@163.com](majie_fzbl@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to o","cbCaip9I2fPqUypc","https://ap.wps.com/l/cbCaip9I2fPqUypc","pdf",1396387,"English","# Background\n## Limitations of current diagnosis and need for screening\n# Methods\n## Study design and participant cohort\n## DNA methylation panel and biomarkers\n## Statistical evaluation (ROC, AUC, sensitivity, specificity, confidence intervals)\n## Comparison with pathological examination and kappa analysis\n## Association testing with demographic characteristics\n# Results\n## Higher methylation levels in ECa versus benign/healthy groups\n## Diagnostic performance (AUC, sensitivity, specificity)\n## Performance by cancer stage\n## Agreement with RT-PCR and pathological gold standard\n## Subgroup assessment (age, gender, other malignancies)\n# Conclusions","[{\"question\":\"Why is a new blood-based diagnostic approach needed for esophageal cancer?\",\"answer\":\"Endoscopy is recommended for high-risk detection but is not suitable for broad screening due to invasiveness and inconvenience. Esophageal cancer also has limited early detection and poor outcomes without timely diagnosis.\"},{\"question\":\"Which DNA methylation biomarkers were included in the proposed panel?\",\"answer\":\"The panel measured DNA methylation levels of SEPTIN9, tissue factor pathway inhibitor 2 (TFPI2), and the fragile histidine triad gene (FHIT).\"},{\"question\":\"How accurate was the panel compared with pathological examination?\",\"answer\":\"The panel showed strong discrimination with an overall ROC AUC of 0.925 (95% CI 0.889–0.952), sensitivity of 79.8%, and specificity of 95.0%. Agreement with the gold-standard pathological examination was supported by a kappa value of 0.725.\"}]","Detection of a novel DNA methylation marker panel for esophageal cancer diagnosis using circulating tumor DNA | PDF",1790011945,25]